CoChat

Omalizumab in children with uncontrolled allergic asthma: Review of clinical trial and real-world experience

Open access
Chipps, Bradley E., Lanier, Bob, Milgrom, Henry, Deschildre, Antoine, Hedlin, Gunilla, Szefler, Stanley J., Kattan, Meyer, Kianifard, Farid, Ortiz, Benjamin, Haselkorn, Tmirah, Iqbal, Ahmar, Rosén, Karin, Trzaskoma, Benjamin, Busse, William W. · 2017 · Journal of Allergy and Clinical Immunology
Cited by 160

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Abstract

Asthma is one of the most common chronic diseases of childhood. Allergen sensitization and high frequencies of comorbid allergic diseases are characteristic of severe asthma in children. Omalizumab, an anti-IgE mAb, is the first targeted biologic therapeutic approved for the treatment of moderate-to-severe persistent allergic asthma (AA) that remains uncontrolled despite high-dose inhaled corticosteroids plus other controller medications. Since its initial licensing for use in adults and adolescents 12 years of age and older, the clinical efficacy, safety, and tolerability of omalizumab have been demonstrated in several published clinical trials in children aged 6 to less than 12 years with moderate-to-severe AA. These studies supported the approval of the pediatric indication (use in children aged ≥6 years) by the European Medicines Agency in 2009 and the US Food and Drug Administration in 2016. After this most recent change in licensing, we review the outcomes from clinical trials in children with persistent AA receiving omalizumab therapy and observational studies from the past 7 years of clinical experience in Europe. Data sources were identified by using PubMed in 2016. Guidelines and management recommendations and materials from the recent US Food and Drug Administration's Pediatric Advisory Committee meeting are also reviewed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaci.2017.03.002

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Cited by

Metadata

Authors
Chipps, B. E., Lanier, B., Milgrom, H., Deschildre, A., Hedlin, G., Szefler, S. J., Kattan, M., Kianifard, F., Ortiz, B., Haselkorn, T., Iqbal, A., Rosén, K., Trzaskoma, B., & Busse, W. W.
Venue
Journal of Allergy and Clinical Immunology
Publisher
Elsevier BV
Published
2017-05
Volume
139
Issue
5
Pages
1431-1444
ISSN
0091-6749 (ISSN-L)
OpenAlex
W2610654869
Cited by
160
References
49
FWCI
13.56
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.